Systemic Immunotherapy for Advanced Cutaneous Squamous Cell Carcinoma

Dai Ogata(Unknown), Tetsuya Tsuchida(Saitama Medical University)

Current Treatment Options in Oncology

March 14, 2019

10.1007/s11864-019-0629-2

Cited by 32

Related Papers

Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity

|Cancer Cell|2022|338

Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patients

|Annals of Oncology|2020|140

Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients

|Journal of Dermatological Science|2015|120

Clinical and histopathological characteristics and survival analysis of 4594 Japanese patients with melanoma

|Cancer Medicine|2019|111

Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study)

|ESMO Open|2021|57